A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs AK 0529 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ark Biosciences
  • Most Recent Events

    • 03 Nov 2017 Status changed from active, no longer recruiting to recruiting.
    • 30 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top